KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Revenue (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Revenue for 18 consecutive years, with $1.2 billion as the latest value for Q1 2026.

  • For Q1 2026, Revenue rose 3790.58% year-over-year to $1.2 billion; the TTM value through Mar 2026 reached $4.3 billion, up 140.31%, while the annual FY2025 figure was $3.7 billion, 65.19% up from the prior year.
  • Revenue hit $1.2 billion in Q1 2026 for Alnylam Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • Across five years, Revenue topped out at $1.2 billion in Q3 2025 and bottomed at $30.0 million in Q1 2025.
  • Average Revenue over 5 years is $554.8 million, with a median of $494.3 million recorded in 2024.
  • Year-over-year, Revenue crashed 93.93% in 2025 and then soared 3790.58% in 2026.
  • Alnylam Pharmaceuticals' Revenue stood at $335.0 million in 2022, then surged by 31.25% to $439.7 million in 2023, then soared by 34.9% to $593.2 million in 2024, then skyrocketed by 84.95% to $1.1 billion in 2025, then increased by 6.39% to $1.2 billion in 2026.
  • According to Business Quant data, Revenue over the past three periods came in at $1.2 billion, $1.1 billion, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.